Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
about
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsCorrelation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential ThrombocytosisDNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms.BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.Prognosis of Primary Myelofibrosis in the Genomic EraMolecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A ReviewSequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.Myeloproliferative neoplasm stem cells.TET2 in Normal and Malignant Hematopoiesis.p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.Targeting cistrome and dysregulated transcriptome of post-MPN sAML.Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
P2860
Q26772881-0CF3B5A0-C966-410B-B984-0F8F189F30CBQ26777265-1022677D-890E-4801-912D-8BFCBA2F1F24Q27853179-A0A61EC6-BDC4-4755-8B95-07B123128CAAQ33595912-1EF18839-B12A-4C95-B6E4-59D232F4FD70Q33751024-01C647C2-A534-4C80-83D8-634E7B0F7215Q37693266-50D8496A-5954-4CDF-A998-75FD124F9751Q38586919-3BFEEB08-5C3C-4734-AC2F-A2FB195E145DQ38613880-6903CA71-C325-4804-89F0-06B56D53FE9AQ38848273-0A6A8048-853F-43E8-AA9E-386DD8C4E7E2Q38926804-E4297E8B-26AA-4E4D-8E32-354D34EFEC1FQ38984558-EC8B9D33-AAE8-4E5C-8715-BE673A1BD06FQ39083031-A7797EB3-4DB9-470F-8783-53C99503CEDEQ39118859-6667D8AD-D9B2-4489-B999-CBB3CE7D9F6EQ39153532-3E687115-9073-411B-B877-5722778A5F0BQ39213887-AFB1BA21-413E-49ED-9068-63F29E860707Q41190385-DE4A8E5A-5EE9-4398-B5DB-8D86AC55BD92Q42334362-239A4ECC-5BBB-40B1-9731-09F22A3E06BAQ44176860-75E39BB6-32A3-480B-A88D-FC7FB439C9ADQ47339574-1D4EC5C7-9385-45F2-B6B0-FEDDA0384301Q48100617-AE4622A0-39E3-4D57-A430-7AC3864ED4A8Q48154859-319D512D-5D3A-4947-A252-3BA6F5A4E418Q48226545-F0CC2DA7-05ED-46D0-8807-202F19B0C7A9Q48284602-3653D4D6-3F4A-424B-93B1-295675E9D7E6Q49344267-DEDFF3AA-02B3-49C4-8EF5-F87FD24AD8F6Q49472515-045B910E-7880-439A-A3D1-85A819C1C80EQ50209900-DAFAA0A9-59EB-44F0-806A-3677159374DCQ51205193-71D80467-789E-4AEF-9DB5-79598E12B26FQ58742961-4065FB1C-DDE4-4072-AF2B-861AFEE65ECD
P2860
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Genomic and functional analysi ...... myeloproliferative neoplasms.
@ast
Genomic and functional analysi ...... myeloproliferative neoplasms.
@en
Genomic and functional analysi ...... myeloproliferative neoplasms.
@nl
type
label
Genomic and functional analysi ...... myeloproliferative neoplasms.
@ast
Genomic and functional analysi ...... myeloproliferative neoplasms.
@en
Genomic and functional analysi ...... myeloproliferative neoplasms.
@nl
prefLabel
Genomic and functional analysi ...... myeloproliferative neoplasms.
@ast
Genomic and functional analysi ...... myeloproliferative neoplasms.
@en
Genomic and functional analysi ...... myeloproliferative neoplasms.
@nl
P2093
P2860
P50
P356
P1476
Genomic and functional analysi ...... f myeloproliferative neoplasms
@en
P2093
Ahmet Dogan
Anna Sophia McKenney
Christopher Y Park
Doron Lipson
Gabriela Chiosis
Geoff A Otto
Marcel R M van den Brink
Michelle Nahas
P2860
P304
P356
10.1073/PNAS.1407792111
P407
P577
2014-12-02T00:00:00Z